Screener
PTC Therapeutics PTCT Interest Expense
Interest Expense at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by PTC Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:InterestIncomeExpenseNonoperatingNet.
The source filing: PTC Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:32 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001070081-26-000012
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Tangible asset impairment and losses on transactions, net | 927 | 77 |
| Total operating expenses | 227,592 | 205,871 |
| Income from operations | 44,959 | 970,225 |
| Interest expense, net | (49,030) | (34,092) |
| Other income (expense), net | 1,609 | (6,305) |
| (Loss) income before income tax expense | (2,462) | 929,828 |
| Income tax expense | (347) | (63,266) |
| Net (loss) income attributable to common stockholders | $(2,809) | $866,562 |
Item 1. Financial Statements (unaudited)
FAQ
- What is PTC Therapeutics's interest expense?
- PTC Therapeutics (PTCT) reported interest expense of -$49.03M in Q1 2026.
- How has PTC Therapeutics's interest expense changed year-over-year?
- PTC Therapeutics's interest expense decreased by 43.8% year-over-year, from -$34.09M to -$49.03M.
- What is the long-term trend for PTC Therapeutics's interest expense?
- Over 4 years (2021 to 2025), PTC Therapeutics's interest expense has grown at a 15.3% compound annual growth rate (CAGR), from -$86.02M to -$152.23M.
- What does interest expense mean?
- Cost of borrowing — interest paid or accrued on bonds, bank loans, credit facilities, finance leases, and other debt obligations.
Ask your AI about PTC Therapeutics's interest expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude